Our review also summarizes recent advances in the clinical development of PI3K and cytoskeleton targeting agents, thereby providing insight into the development of novel therapeutic approaches targeting the interplay between PI3K and the cytoskeleton for cancer management. Here, PIK3CA is linked to cancer.